Analysts expect Affimed (NASDAQ:AFMD) to announce earnings per share (EPS) of ($0.17) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Affimed’s earnings, with estimates ranging from ($0.23) to ($0.05). Affimed posted earnings per share of ($0.20) during the same quarter last year, which would indicate a positive year over year growth rate of 15%. The firm is expected to report its next quarterly earnings report on Thursday, April 21st.
On average, analysts expect that Affimed will report full year earnings of ($0.53) per share for the current fiscal year, with EPS estimates ranging from ($0.66) to ($0.38). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.46) per share, with EPS estimates ranging from ($1.19) to $0.52. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover Affimed.
Affimed (NASDAQ:AFMD) last announced its quarterly earnings data on Wednesday, November 10th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.01). Affimed had a negative net margin of 132.18% and a negative return on equity of 40.23%. During the same period in the prior year, the business earned ($0.08) earnings per share.
AFMD traded up $0.26 during mid-day trading on Friday, reaching $7.07. The stock had a trading volume of 2,607,580 shares, compared to its average volume of 2,052,802. Affimed has a 52 week low of $4.78 and a 52 week high of $11.74. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.06 and a current ratio of 3.07. The stock has a market capitalization of $694.89 million, a P/E ratio of -12.85 and a beta of 2.58. The firm’s fifty day simple moving average is $6.28 and its two-hundred day simple moving average is $7.05.
Several large investors have recently added to or reduced their stakes in the stock. Altium Capital Management LP acquired a new stake in shares of Affimed in the third quarter valued at about $4,110,000. BNP Paribas Arbitrage SA increased its position in shares of Affimed by 483.3% in the third quarter. BNP Paribas Arbitrage SA now owns 24,940 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 20,664 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Affimed by 126.4% in the third quarter. Janus Henderson Group PLC now owns 1,192,364 shares of the biopharmaceutical company’s stock valued at $7,375,000 after acquiring an additional 665,656 shares during the last quarter. Intellectus Partners LLC increased its position in shares of Affimed by 20.7% in the third quarter. Intellectus Partners LLC now owns 188,400 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 32,300 shares during the last quarter. Finally, Telemetry Investments L.L.C. increased its position in shares of Affimed by 47.0% in the third quarter. Telemetry Investments L.L.C. now owns 131,018 shares of the biopharmaceutical company’s stock valued at $810,000 after acquiring an additional 41,910 shares during the last quarter. 73.02% of the stock is currently owned by institutional investors and hedge funds.
Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA.
Further Reading: ESG Score
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.